Ryan Mercer, MD
Ophthalmology · Columbia, SCNPI 1598129298
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 361 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations.
Across 361 payments — averaging $24.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Alcon$2K
- Sun Pharmaceutical Industries Inc.$781
- Biotissue Holdings Inc.$528
- Glaukos Corporation$494
- Novartis$395
- plus $3K from 17 others
What the payments were for
- Food & beverage$8,996100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 67 | $2,073 |
| Alcon | 71 | $1,859 |
| Sun Pharmaceutical Industries Inc. | 59 | $781 |
| Biotissue Holdings Inc. | 6 | $528 |
| Glaukos Corporation | 9 | $494 |
| Novartis | 15 | $395 |
| Bausch & Lomb Americas Inc. | 25 | $383 |
| Ocular Therapeutix, Inc. | 17 | $310 |
| Sight Sciences, Inc. | 15 | $307 |
| Tarsus Pharmaceuticals, Inc. | 11 | $268 |
| NEW World Medical,inc. | 3 | $212 |
| Oyster Point Pharma, Inc. | 11 | $209 |
| Amgen(2 entities) | 9 | $184 |
| Mallinckrodt Hospital Products Inc. | 7 | $175 |
| Rayner Intraocular Lenses Limited | 8 | $159 |
| Dompe US, Inc. | 7 | $154 |
| Harrow Eye, LLC | 7 | $132 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $107 |
| Thea Pharma Inc. | 2 | $78 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $64 |
| Kala Pharmaceuticals, Inc. | 3 | $52 |
| Lensar, Inc. | 1 | $43 |
| Eyevance Pharmaceuticals LLC | 2 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$623
- Hydrus Microstent$252
- AcrySof IQ VIVITY IOL$219
- XEN GLAUCOMA TREATMENT SYSTEM$147
- Clareon$138
- KXL System$135
- Photrexa$135
How this compares
$8,996 in reported general payments places this provider in the 85th percentile of 293 ophthalmology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 98 | $101,104 |
| LumiganBimatoprost | 151 | $73,968 |
| RocklatanNetarsudil Mesylat/Latanoprost | 119 | $46,783 |
| CequaCyclosporine | 61 | $41,016 |
| Cyclosporine | 77 | $37,649 |
| XiidraLifitegrast | 15 | $22,853 |
| IlevroNepafenac | 46 | $17,144 |
| CombiganBrimonidine Tartrate/Timolol | 47 | $17,039 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 75 | $14,414 |
| MieboPerfluorohexyloctane/Pf | 19 | $14,316 |
| VyzultaLatanoprostene Bunod | 28 | $12,738 |
| ProlensaBromfenac Sodium | 33 | $11,934 |
| Prednisolone Acetate | 211 | $11,584 |
| Alphagan PBrimonidine Tartrate | 24 | $11,053 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 29 | $9,496 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $2,073 | $203,164320 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $383 | $49,90762 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $781 | $41,01661 claims |
| NovartisIlevro | $395 | $17,14446 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm | $64 | $15,85149 claims |
| AlconSimbrinza | $1,859 | $9,49629 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 293 ophthalmology providers in South Carolina.
Other ophthalmology in Columbia
- Matthew ClaryColumbia$119K
- Willard HarmsColumbia$14K
- Robert HuffColumbia$13K
- Stephen CrossColumbia$11K
- Lucas PlattColumbia$7K
- Kerry SolomonMt Pleasant$1.7M
- William ClarkWest Columbia$768K
- George WaringMt Pleasant$645K
- Karolinne RochaCharleston$552K
- Joseph BishopHilton Head Island$136K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.